Amgen’s diversified growth portfolio is absorbing biosimilar erosion, while MariTide creates asymmetric metabolic upside despite leverage and major legal risks.
Overview
Amgen is a diversified global biotechnology company whose revenue is primarily generated by innovative biologic medicines and biosimilars, supplemented by collaboration, milestone, and royalty income. Its six therapeutic platforms span cardiovascular disease, bone health, oncology, rare diseases, inflammation, and biosimilars. The investment case is a transition from declining legacy blockbusters toward faster-growing assets, with **MariTide providing substantial metabolic optionality** and Repatha, Evenity, Tezspire, Uplizna, and Imdelltra already demonstrating strong commercial momentum. Q2 2026 revenue rose 10% year over year to $10.1 billion, beating consensus by approximately 7.1%, while non-GAAP EPS of $6.29 exceeded consensus by $0.69. Management raised 2026 revenue guidance to $38.2-$39.4 billion and non-GAAP EPS guidance to $22.30-$23.50. The stock closed at $390.02, near its $391.42 all-time high, after gaining 17.58% over three months and 29.97% over twelve months. The report’s probability-weighted five-year share-price target is $558.02, supported by a $525.71 base case and $832.77 bull case, although the $10.7 billion IRS dispute, Tavneos withdrawal risk, leverage, and MariTide execution remain material constraints.